CD274 and neoplasm: Increased DNA damage by PARP inhibitors may alter tumor immunogenicity and sensitize tumors to PD‐1/PD‐L1 blockade, possibly triggering more durable PD‐1/PD‐L1 blockade than single‐drug antitumor response [18].